VentriPoint Diagnostics Ltd. VPTDF Archives - Page 2 of 2

MondayMay 06, 2013 2:04 pm

VentriPoint Diagnostics Ltd. (VPTDF) and the MRI Alternative

Since its gradual development, from initial concepts in the 1950s to experimental machines in the 1970s and 1980s, MRI based imaging in its various iterations has grown to become a multi-billion global industry, with a market that continues to increase as an aging population feeds the need for heart, cancer, and neurological related diagnostics. Hospitals all over the world demand the machines, given their ability to reveal the internal structures of the body in significant detail, but it’s a technology that comes at a price. Even small scale systems can cost hundreds of thousands of dollars, with large scale high-power…

TuesdayApr 30, 2013 8:23 am

VentriPoint Diagnostics Ltd. (VPTDF) Receives Expanded License from Health Canada

Today, VentriPoint Diagnostics reported receiving an expanded license from Health Canada that allows the company to sell the VMS™ heart analysis system for clinical use in Canada. The expansion was for the NRV™ application for the analysis of 2-D ultrasound images for patients with non-specific heart disease. The NRV™ application will enable healthcare providers to rapidly and accurately assess the status of the right ventricle in all patients that do not have significant congenital heart defects or pulmonary hypertension, yet may have a variety of other conditions. VentriPoint’s VMS-2DE™ heart analysis system will be used in conjunction with the NRV™…

ThursdayApr 25, 2013 8:37 am

VentriPoint Diagnostics, Inc. (VPTDF) Reports FDA Response to 510 (k) Submission for Pulmonary Arterial Hypertension

VentriPoint Diagnostics, creator of the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function, announced that the U.S. Food and Drug Administration (FDA) responded to its Pulmonary Arterial Hypertension (PAH) 510(k) submission with a short list of suggestions, clarifications and requests for additional information. "We are very pleased the FDA has reviewed our submission so expeditiously and we now have a small number of modifications to the filing to prepare," said, Dr. George Adams, CEO of VentriPoint. Known as the most serious form of the five recognized groups of pulmonary hypertension, PAH is a devastating disease with…

WednesdayApr 24, 2013 12:21 pm

The Case for VentriPoint Diagnostics Ltd. (VPTDF)

If you think that you’re safe from heart disease, America’s #1 killer, think again. There’s a good chance that you are at risk, and simply don’t know it. In fact, approximately half of all people, both men and women, who die from heart attack each year had no prior knowledge of their own heart disease. It’s the reason that researchers around the world are anxious to improve diagnostic technologies, with an eye toward saving potentially millions of lives that will otherwise be lost. One of the newest diagnostic technologies now available for doctors in the fight against heart disease is…

WednesdayApr 17, 2013 8:39 am

VentriPoint Diagnostics Ltd. (VPTDF) Receives CE Mark for NRV™ Application, Vastly Expands Capabilities

Today, VentriPoint Diagnostics, developer of ultrasound tools used on patients with heart disease, announced that the European Notified Body, Intertek Semko AB, has granted a CE Mark for its NRV™ application, which pertains to the analysis of 2-D ultrasound images for patients with non-specific heart disease. The application will allow clinicians to rapidly and accurately assess the status of the right ventricle in patients without significant congenital heart defects or pulmonary hypertension, but who may have a variety of other conditions (such as left-heart failure or valve disease). The NRV™ database can be used in conjunction with the VMS-2DE™ heart…

WednesdayApr 10, 2013 1:50 pm

VentriPoint Diagnostics Ltd. (VPTDF) Changes the Way Doctors Look at Hearts

VentriPoint Diagnostics, a Seattle-based heart analysis technology company, is in the process of changing the way hearts are analyzed, a significant venture given the size of the market. According to the American Heart Association, there are approximately 80 million U.S. adults experiencing some form of cardiovascular disease, representing an annual total cost of nearly $500 billion. However, in spite of advances in ultrasound, MRI, and other non-invasive diagnostic technologies, there are currently a number of problems with accurate heart diagnosis. In particular, accurate analysis of what is called the “right heart” has been problematic. The right side of the heart…

WednesdayApr 03, 2013 1:32 pm

Busy March Sets the Stage for VentriPoint Diagnostics Ltd. (VPTDF)

March was a busy month for VentriPoint Diagnostics, a Canadian based medical device company focused on revolutionary software for 3D heart analysis. The company was successful in completing several important steps in the development and approval of what is viewed as potentially transformative diagnostics technology. March began with the announcement that the company had received acceptance from the FDA (U.S.) of its submission for right heart analysis in Pulmonary Arterial Hypertension (PAH), meaning that all of the required information is present for the FDA to proceed with a substantive review. PAH is a devastating disease, which can affect individuals from…

WednesdayMar 27, 2013 10:42 am

VentriPoint Diagnostics Ltd. (VPTDF) Offers New Hope for CHD Patients

One of the challenges facing heart doctors is working with people having congenital heart disease (CHD). It’s a growing problem that involves unique issues. Though CHD is usually associated with children, a recent article by Michael O'Riordan in Clinical Cardiology (http://dtg.fm/5AjT) references a report indicating that the frequency of hospitalizations among adults for congenital defects has grown twice as fast as for children, with annual adult admissions now over a third of total CHD admissions. Among other factors, people who used to die young from such problems are now often living well into adulthood. The result is a growing burden…

ThursdayMar 21, 2013 8:38 am

VentriPoint Diagnostics Ltd. (VPTDF) Pursues European and Canadian Approvals for New Non-Specific Heart Disease Application

Today before the opening bell, VentriPoint Diagnostics announced it has filed for CE Mark and Health Canada approvals for its database for non-specific heart disease (NRV). By using this database, clinicians can rapidly and accurately assess the status of the right ventricle (RV) in all patients that do not have significant congenital heart defects or Pulmonary Arterial Hypertension (PAH), yet may have a variety of other conditions, such as left-heart failure or valve disease. "Our customers have asked for the NRV application so they can assess the RV in virtually every patient they see," said Dr. George Adams, CEO of…

FridayMar 15, 2013 6:04 pm

VentriPoint Diagnostics Ltd. (VPTDF) is "One to Watch"

VentriPoint Diagnostics leverages knowledge-based techniques to make heart analysis more convenient and less expensive. Having already installed multiple VMS™ analysis systems for heart testing in leading cardiac centers in Europe, Canada and the United States, the company is currently focused on expanding the applications of its technology beyond congenital heart disease in adults and children. VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. The company designed its analysis system to be used for all major heart diseases, including pulmonary hypertension, cardiovascular disease, and heart failure. Canada and Europe (CE Mark) have granted approval…

Site Search

Company Search

Tag: VentriPoint Diagnostics Ltd. VPTDF